Valneva withdraws application for standard US approval of its chikungunya shot

Core Viewpoint - French drugmaker Valneva has voluntarily withdrawn its application for standard approval of its chikungunya vaccine in the United States following the FDA's suspension of the vaccine's licensing process [1] Company Summary - Valneva's decision to withdraw the application indicates challenges in the regulatory approval process for its chikungunya vaccine [1] - The FDA's suspension of the vaccine's licensing process suggests potential concerns regarding the vaccine's safety or efficacy [1]